Search

Your search keyword '"S. Pablo Sardi"' showing total 67 results

Search Constraints

Start Over You searched for: Author "S. Pablo Sardi" Remove constraint Author: "S. Pablo Sardi"
67 results on '"S. Pablo Sardi"'

Search Results

1. Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer’s disease

2. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model

3. Accelerating diagnosis of Parkinson’s disease through risk prediction

4. Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis

5. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration

6. Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease

7. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons

9. Enforced dimerization between XBP1s and ATF6f enhances the protective effects of the UPR in models of neurodegeneration

10. The Mutation Matters: <scp>CSF</scp> Profiles of <scp>GCase</scp> , Sphingolipids, α‐Synuclein in <scp> PD GBA </scp>

11. GALCvariants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease

12. GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson's disease

13. Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease

15. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model

16. Viral alpha-synuclein knockdown prevents spreading synucleinopathy

17. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration

18. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases

19. Accelerating diagnosis of Parkinson’s disease through risk prediction

20. Sterol auto-oxidation adversely affects human motor neuron viability and is a neuropathological feature of amyotrophic lateral sclerosis

21. Additional file 1 of Accelerating diagnosis of Parkinson’s disease through risk prediction

22. Parkinson's disease: Genetic-driven therapeutic approaches

23. The commercial genetic testing landscape for Parkinson's disease

24. Contributors

25. Genome-Wide Polygenic Risk Score Identifies Individuals at Elevated Parkinson’s Disease Risk

26. Control of mammalian brain ageing by the unfolded protein response transcription factor XBP1

27. Insulin-like growth factor 2 (IGF2) protects against Huntington's disease through the extracellular disposal of protein aggregates

28. Network Analysis and Human Single Cell Brain Transcriptomics Reveal Novel Aspects of Alpha-Synuclein (SNCA) Biology

29. Neutral Lipid Cacostasis Contributes to Disease Pathogenesis in Amyotrophic Lateral Sclerosis

30. Control of mammalian brain aging by the unfolded protein response (UPR)

31. Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases

32. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic

33. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease

34. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models

35. Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease

36. Miglustat does not enhance alglucosidase alfa or avalglucosidase alfa efficacy in Pompe mice

37. Oral venglustat in Parkinson disease patients with a mutation: Study design of part 2 of the MOVES-PD trial and patient characteristics

38. Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in Parkinson disease patients with a GBA mutation from Japan and the rest of the world: Results from part 1 of the MOVES-PD study

39. New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics

40. Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy

41. New Frontiers in Parkinson's Disease: From Genetics to the Clinic

42. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic

43. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease

44. Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle

45. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease

46. Gene Transfer to the CNS Is Efficacious in Immune-primed Mice Harboring Physiologically Relevant Titers of Anti-AAV Antibodies

47. Mutant GBA1 Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models

49. Neuregulin-1 Signaling in Brain Endothelial Cells

50. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders

Catalog

Books, media, physical & digital resources